1 / 7

Pharmaceutical Biotech Group

U.S. Irritable Bowel Syndrome Therapeutics Markets Promoting Awareness and Understanding of Irritable Bowel Syndrome (IBS) Stimulates Demand for Treatment.

klaus
Download Presentation

Pharmaceutical Biotech Group

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. U.S. Irritable Bowel Syndrome Therapeutics MarketsPromoting Awareness and Understanding of Irritable Bowel Syndrome (IBS) Stimulates Demand for Treatment “Market penetration is significantly lower than prevalence rates, ensuring expansion, as general awareness grows, physicians gain a better understanding of the disorder, and a pipeline of drugs that address unmet needs become available.” Pharmaceutical Biotech Group

  2. Industry Trends • The entry of top-tier pharmaceutical companies into the market with novel drugs resulting in increased awareness of IBS as a disorder • 5-HT modulators have expanded the market and driven revenue growth • Sections of the patient population still in need of effective multiple symptom treatment options • The approvals of cilansetron and renzapride and the continued reliance on patient driven demand, fueled by extensive promotional and educational campaigns are expected to drive treatment rates and revenues

  3. Key Features • Frost & Sullivan Provides: • Detailed insights into recent developments and trends • Drivers, restraints, challenges, and strategic recommendations • Analyst insights on emerging issues and pipeline drugs in the IBS market • Market sizing and competitive analysis • Market forecasts and opportunity analysis • End-user analysis within each report

  4. What We Offer • Global Coverage: The United States • Proven methodology encompassing extensive primary and secondary • data and research • Information and strategies that cover business and technology issues • Credible data and analysis highlighting industry dynamics • Winning strategies to help you create precise business plans

  5. Who Will Benefit? Current Market Participants • Find out how you can compete now that the landscape has changed • Assess current and future drivers and restraints • Determine and exploit new market share opportunities New Entrants • Analyze challenges associated with the irritable bowel syndrome market • Calculate time scales for strategy implementation • Position yourself to capitalize on the market’s unmet needs Investment Community • Analyze long-term strategies of companies in the market • Determine which participants will outperform the competition • Assess attractiveness of investing in IBS market

  6. Key Market Participants • Alizyme • Amarin Corp. • AstraZeneca • Aventis • Axcan Pharma, Inc. • Bertek Pharmaceuticals • Boehringer Ingelheim • Bradley Pharmaceuticals, Inc. • Braintree Laboratories • Bristol-Myers Squibb • Eli Lilly • First Horizon • Forest Laboratories • GlaxoSmithKline • InKine Pharmaceutical Co., Inc. • Johnson & Johnson • Novartis AG • Organon • Par Pharmaceutical • PBM Pharmaceuticals • Pfizer, Inc. • Schwarz Pharma AG • Solvay S.A. • Tyco Healthcare • Valeant Pharmaceuticals • Wyeth-Ayerst

  7. For More Information • Call toll free: 877 GO FROST (877.463.7876) • Fax toll free: 888.690.3329 • E-mail: myfrost@frost.com • Visit: www.frost.com

More Related